<DOC>
	<DOCNO>NCT00060138</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Zoledronate may prevent bone loss stop growth tumor cell bone . It yet know whether monoclonal antibody effective zoledronate treat woman breast cancer bone metastasis . PURPOSE : Randomized phase I/II trial compare effectiveness monoclonal antibody zoledronate treat woman breast cancer bone metastasis .</brief_summary>
	<brief_title>Monoclonal Antibody Compared With Zoledronate Treating Women With Breast Cancer Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Compare safety tolerability monoclonal antibody CAL v zoledronate woman breast cancer bone metastasis . - Compare , preliminarily , potential effect drug skeletal events/manifestations relate bone metastasis , include hypercalcemia , bone pain , bone metastatic lesion , complication ( e.g. , pathologic fracture spinal cord compression ) , intervention ( e.g. , surgery radiotherapy ) patient . - Compare change ECOG performance status patient treat drug . - Determine pharmacokinetics monoclonal antibody CAL patient . OUTLINE : This randomize , double-blind , multicenter study . Patients stratify accord average prestudy pain score question 3 daily electronic telephone pain diary ( less 3 v 3 ) prior bisphosphonate therapy ( yes v ) . Patients randomize 1 4 treatment arm . - Arm I : Patients receive monoclonal antibody CAL IV 30-60 minute day 1 . - Arm II : Patients receive low dose monoclonal antibody CAL arm I . - Arm III : Patients receive low dose ( low arm II ) monoclonal antibody CAL arm I . - Arm IV : Patients receive zoledronate IV 30-60 minute day 1 . Treatment arm repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients keep pain diary throughout study participation . Patients follow 24 week . PROJECTED ACCRUAL : A total 72 patient ( 18 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Paraneoplastic Syndromes</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer Radiographical evidence least 1 bone metastasis No prior radiotherapy surgery bone metastasis No radiotherapy surgery anticipate bone metastasis within next 24 week Bone pain severity score least 1 5 7 day determine question 3 Brief Pain Inventory ( BPI ) No bone metastases weightbearing bone imminent risk pathologic fracture surgical intervention No vertebral metastasis place patient imminent risk spinal cord compression Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Pre postmenopausal Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic WBC least 2,000/mm^3 Lymphocyte count least 500/mm^3 Granulocyte count least 1,000/mm^3 Platelet count least 50,000/mm^3 Hepatic ALT AST great 2.5 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN Renal Calcium great 10.1 mg/dL No oliguria , define less 30 mL urine per 2hour collection No acute renal failure Creatinine great 2.5 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No sepsis No know anticipate contraindication study drug PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 3 week since initiation new chemotherapy regimen Endocrine therapy More 3 week since initiation new hormonal therapy regimen Radiotherapy See Disease Characteristics More 3 week since prior radiotherapy Surgery See Disease Characteristics Other More 60 day since prior bisphosphonates More 30 day since prior investigational drug No change analgesic drug regimen screen period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>hypercalcemia malignancy</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>pain</keyword>
</DOC>